Researchers found that tumors with high levels of stroma are twice as likely to exhibit chemoresistance to conventional treatment. The study aims to utilize a readily obtainable biomarker, TSP, to tailor more effective treatments for patients diagnosed with ovarian cancer.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
Researchers have developed a new urine-based test for early detection of ovarian cancer using nanopore sensing technology. The method can simultaneously identify multiple peptides, including those derived from LRG-1, and shows promise for improving 5-year survival rates by up to 75%.
A new mathematical model predicts that ovarian tissue freezing can potentially delay or eliminate menopause in healthy women. The study, led by Yale University's Kutluk Oktay, uses data from hundreds of previous procedures to estimate the maximum number of years menopause can be delayed, with younger women showing greater promise.
Researchers have developed an AI-driven test that accurately diagnoses ovarian cancer in women clinically classified as normal, improving detection of early-stage disease. The test uses machine learning and blood metabolite information to assign a probability of disease presence or absence, offering a more clinically informative approach.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers found that ovarian cancer cells spread more easily in tissues that are senescent or aged due to the secretion of a unique extracellular matrix. This matrix attracts cancer cells and allows them to attach and spread faster, potentially leading to worse outcomes in older populations.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Researchers found that ASCOT reverses some age-related protein expression changes, enriching processes related to the complement cascade and immune system in patients with poor ovarian response. In contrast, patients with premature ovarian insufficiency showed enrichment in responses to oxygen-containing compounds and growth hormones.
A Wayne State University study reports progress in a therapeutic approach that can restore immune surveillance and provide long-term protection against ovarian cancer tumors. The therapy, CARG-2020, has shown promise in animal models and may prove more effective than existing immunotherapies.
A study found that patients with hormone receptor-positive breast cancer who paused endocrine therapy to conceive did not experience worse short-term recurrence rates. Cryopreserved embryo transfer was associated with higher pregnancy rates, and younger age and menstrual cycles returning after pausing therapy were linked to improved ou...
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
A new AI-based model, IRON, analyzes patient clinical features and tumor characteristics to predict therapy response in high-grade ovarian cancer patients. The model achieved an 80% accuracy rate, significantly better than current clinical methods.
Researchers created an immunodeficient mouse model of physiological ovarian aging, mirroring female fertility decline with age. The study found decreased oocyte quality, impaired follicle activation and growth, and increased mitochondrial dysfunctions in Old mice.
Researchers at The Wistar Institute have engineered novel monoclonal antibodies that engage Natural Killer cells through Siglec-7, a conserved glyco-immune marker, to fight against cancer. These new approaches demonstrate preclinical feasibility and potential for treating treatment-resistant ovarian cancers.
A new nuclear medicine treatment has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting. The therapy targets the HER2 protein and achieved high potency while maintaining an acceptable safety profile.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers discovered ovarian mesenchymal progenitor cells that improve aged ovarian function and extend reproductive lifespan. By transplanting functional mesenchymal cells, the study shows an efficient approach to postpone ovarian aging.
A new study led by Fred Hutchinson Cancer Center identified a 64-protein pattern that predicted ovarian tumor responsiveness to treatment. This diagnostic could identify patients with types of ovarian cancers that would not benefit from standard therapies, allowing them to pursue clinical trials instead.
Researchers have discovered a 64-protein signature that can predict which ovarian cancer patients are unlikely to respond to chemotherapy, paving the way for personalized treatment options. The study also identifies five new subtypes of high-grade serous ovarian cancer, suggesting different treatment strategies may be needed.
Brigham researchers use induced pluripotent stem cells to restore hormone production and fertility in mice with premature ovarian failure. The study shows promise for treating incurable conditions and may lead to new therapies for patients with ovarian failure.
Researchers discovered that obesity affects ovarian cancer by altering the tumor's immune microenvironment and stiffening surrounding tissue. This change impairs treatment response to chemotherapy, leading to poorer survival rates among patients with high body mass index (BMI).
A new study reveals that cancer cells reprogram normal mesothelial cells into cancer-associated mesothelial cells through the AMH axis, promoting tumor growth and immune evasion. Disrupting this signal slows tumor growth and helps the immune system overcome some of its defenses.
A synoptic report improved the completeness of pretreatment CT reports in patients with advanced ovarian cancer. Involvement of surgically established unresectable or challenging-to-resect disease sites was mentioned in all disease-specific synoptic reports, compared to 37% of simple structured reports.
A case-control study found associations between certain jobs and increased risks of ovarian cancer. Hairdressers, beauticians, and accountants were linked to higher risks, with cumulative exposure to agents like talcum powder and ammonia also contributing.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
A nationwide study of nearly two million women found that those with PCOS who have undergone menopause are more than twice as likely to be diagnosed with ovarian cancer. The risk was also significantly higher for a type of ovarian tumor known as serous borderline, which can lead to cancer later on.
Researchers at Imperial College London have found that tumors with tertiary lymphoid structures (TLS) in high-grade ovarian cancer respond better to treatment. Genes like IL15 and CXCL10 play a role in TLS formation, while DCAF15 interacts with these tissues. An AI algorithm can detect TLS on CT scans, enabling early identification of ...
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Researchers have identified three subtypes of ovarian high-grade serous carcinoma (HGSC) based on genomic changes, which may help tailor therapies. The study's findings could improve treatment outcomes for patients with this aggressive subtype.
A recent Fred Hutchinson Cancer Center study found that fibroids were associated with an increased risk of ovarian cancer in both Black and white women, while hysterectomy modified this risk for white women but not Black women. The study highlights the need for further research into racial disparities in ovarian cancer risk.
Researchers have reported promising results in rare gynecologic cancers from the DART immunotherapy trial, with durable responses and complete remissions observed in patients. The findings suggest a potential new treatment approach for these previously underserved patient populations.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
A new target for drug-resistant ovarian cancer has been identified through a preclinical study led by researchers at Penn Medicine. An antibody-drug conjugate targeting B7-H4 showed significant anti-tumor activity and sustained response in treatment-resistant models.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
Scientists at the Wyss Institute and Gameto develop a living, fully human ovarian organoid that supports egg cell maturation and secretes sex hormones. This technology enables the study of human ovarian biology without tissue from patients and could lead to new treatments for infertility and ovarian cancer.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
A study found a link between pain and indigestion medication purchases and ovarian cancer diagnoses, suggesting earlier symptom recognition. The research suggests that loyalty card data can be used to identify potential ovarian cancer cases.
A study suggests that loyalty card data on over-the-counter medicine purchases could help spot ovarian cancer cases earlier. Women with ovarian cancer were found to buy more pain and indigestion medications before diagnosis, often up to 8 months prior. This could lead to improved survival rates if symptoms are picked up earlier.
A study by Mayo Clinic researchers found a specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer. The discovery strengthens evidence that the bacterial component of the microbiome is an important indicator for early detection, diagnosis, and prognosis of ovarian cancer.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
Researchers at Memorial Sloan Kettering Cancer Center have discovered several mechanisms of immune escape that contribute to ovarian cancer's resistance to immunotherapy. The study reveals that ovarian tumors develop new mutations to evade the immune system as they spread, making it challenging to identify a marker for predicting respo...
A new machine learning fusion model has been developed to diagnose ovarian cancer more accurately by combining ultrasound and photoacoustic tomography imaging. The model achieved an accuracy of 90% in detecting ovarian lesions, outperforming previous methods.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
Research suggests that antibiotics used in ovarian cancer treatment can accelerate cancer progression and lower survival rates. Reintroducing healthy gut bacteria may slow down cancer growth and restore sensitivity to chemotherapy.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
Two new discoveries led by Cedars-Sinai Cancer investigators improve understanding of ovarian cancer's development and suggest personalized therapeutic approaches. They identified four new genetic regions linked to increased ovarian cancer risk and found that some tumors may develop resistance to chemotherapy from an early stage.
A global study found that early-stage mucinous ovarian cancer patients with an infiltrative pattern of invasion have poorer survival chances. This discovery could lead to more targeted treatment strategies for these patients. Researchers hope to develop targeted drugs and align treatment guidelines worldwide.
Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.
Researchers deciphered the ovarian reserve in cynomolgus monkeys using quantitative morphometric study. The study found that the number of primordial follicles decreased with age, with abundant reserves in perinatal periods and sharp decline during adolescence and adulthood.
Researchers at Oregon State University have developed a promising messenger RNA therapy for ovarian cancer, which also shows promise in treating cachexia, a muscle-wasting condition associated with cancer. The treatment uses lipid nanoparticles to deliver mRNA that triggers the production of the follistatin protein within cancer clusters.
A new study has successfully predicted ovarian cancer in patients with a pelvic mass using a simple blood test. The liquid biopsy technology captures circulating tumor cells, allowing for genetic analysis in just a couple of hours, which can help diagnose the disease earlier.
Researchers found that neonatal serum ketone body production determines the quantity and quality of primordial follicles, reducing ROS-induced apoptosis. This mechanism is crucial for maintaining ovarian capacity and preventing premature ovarian aging.
Researchers identify PRC1 as key to establishing and maintaining ovarian reserve, providing insights into female reproductive health and lifespan. The study's findings may help explain premature ovarian failure and infertility in humans.
A new study published in the Journal of Clinical Oncology found that frequent aspirin use is linked with a 13% reduced risk of ovarian cancer in individuals with multiple risk factors. Aspirin benefitted most subgroups, including those with endometriosis and obesity.